KLK3 and cancer: For the FHCRC model, systematic differences in survival for Gleason 6 and 7 cancers, which are indirectly driven by differences in PSA growth rates and treatment assignment by Gleason score, are modest and appear to be swamped by Monte Carlo variation in our simulations.